The rhGH Accretropin has the amino acid sequence identical to that of human growth hormone of pituitary origin and the product is intended for subcutaneous injection. The indication of the drug Accretropin is for the treatment of growth failure in children with growth hormone deficiency as well as short build physique associated with Turner Syndrome. Accretropin has been developed under the research and development agreement with the Apotex Group having Cangenea's majority shareholdings.

Cangeneâ's rhGH Accretropin is identical in succession to naturally produced human growth hormone of pituitary gland source and is manufactured in the biotechnology manufacturing facility of the company at Winnipeg, Manitoba. The natural human growth hormone is the protein generated by the pituitary gland that functions on the long bones of the body until onset of puberty as well as promotes the growth of normal physical build. The deficit of natural human growth hormone during the early childhood results in the unusually smaller physical build.

Some more approved human growth hormone products designed and developed by various other companies of the world also compete for the huge international markets. Turner Syndrome is the known as the x-chromosome related disorder found in the girls that causes the short physical build as well as infertility disorders.